title: Effect of phoshpodiesterase 4 (PDE4) inhibibtors on eotaxin expression in humen bronchial epithelial cells.
abstract: The increasing number of eosinophils into bronchoaelvolar space is observed during noninfectious inflammatory lung diseases. Eotaxins (eotaxin-1/CCL11, eotaxin-2/CCL24, eotaxin-3/CCL26) are the strongest chemotactic agents for eosinophils. Inhibitors of phosphodiesterase 4 (PDE4), the enzyme decomposing cAMP, are anti-inflammatory agents which act through cAMP elevation and inhibit numerous steps of allergic inflammation. The effect of PDE4 inhibitors on eotaxin expression is not known in details. The aim of our study was to evaluate the influence of PDE4 inhibitors: rolipram and RO-20-1724 on expression of eotaxins in bronchial epithelial cell line BEAS-2B. Cells were preincubated with PDE4 inhibitors or dexamethasone for 1 hour and then stimulated with IL-4 or IL-13 alone or in combination with TNF-α. After 48 hours eotaxin protein level was measured by ELISA and mRNA level by real time PCR.
  
  
  RESULTS
  PDE4 inhibitors decreased CCL11 and CCL26 expression only in cultures co-stimulated with TNF-α. In cultures stimulated with IL-4 and TNF-α rolipram and RO-20-1724 diminished CCL11 mRNA expression by 34 and 37%, respectively, and CCL26 by 43 and 47%. In cultures stimulated with IL-13 and TNF-α rolipram and RO-20-1724 decreased expression of both eotaxins by about 50%. These results were confirmed at the protein level. The effect of PDE4 inhibitors on eotaxin expression in BEAS-2B cells, in our experimental conditions, depends on TNF-α contribution.
authors: Department of Internal Diseases, Pneumonology and Allergology Medical University of Warsaw, Warsaw, Poland. mpaplinska@wum.edu.pl
authors: M
authors: M
authors: Paplinska
authors: R
authors: R
authors: Chazan
authors: H
authors: H
authors: Grubek-Jaworska
mesh_terms: D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001980:Bronchi / Q000166:cytology / Q000378:metabolism; D018929:Cell Culture Techniques; D054413:Chemokine CCL11 / Q000096:biosynthesis* / Q000235:genetics; D054423:Chemokine CCL24 / Q000096:biosynthesis* / Q000235:genetics; D000075906:Chemokine CCL26; D019742:Chemokines, CC / Q000096:biosynthesis* / Q000235:genetics; D016207:Cytokines / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D004804:Eosinophils / Q000378:metabolism; D004847:Epithelial Cells; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000494:pharmacology*; D020889:Rolipram / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; C120429:CCL26 protein, human; D054413:Chemokine CCL11; D054423:Chemokine CCL24; D000075906:Chemokine CCL26; D019742:Chemokines, CC; D016207:Cytokines; D058988:Phosphodiesterase 4 Inhibitors; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D003907:Dexamethasone; D020889:Rolipram